BNTX - Latest News

BioNTech SE (BNTX), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $22.36B. Beta to the broader market is 1.25.

The article list below shows the most recent BNTX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent BNTX Headlines

BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX)

prnewswire.com - Oct 14, 2026

BioNTech investors absorbed a 7. 13% loss when the AHEAD-MERIT trial of BNT113 missed its progression-free survival primary endpoint.

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

globenewswire.com - Oct 13, 2026

MAINZ, Germany, October 13, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the first topline results from the AHEAD-ME

Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?

fool.com - Oct 13, 2026

Moderna's market cap has soared on positive results for its mRNA cancer vaccine. Meanwhile, BioNTech has floundered after disappointing clinical resu

Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines

zacks.com - Oct 12, 2026

MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research fundi

BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 36,209 Shares

defenseworld.net - Oct 11, 2026

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 36,209 shares of the company's stock in a transaction that occurred on

How News Affects BNTX Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track BNTX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked BNTX news questions

What is the latest BNTX news headline?

The most recent BNTX headline (Oct 14, 2026) is "BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX)". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the BNTX news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What BNTX news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual BNTX options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.